Investor Presentaiton
Hematology
Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
Aggressive development plan to move into earlier lines and
leverage proprietary combinations
RRMM 1-3 prior lines
alnuctamab monotherapy vs
Investigator's Choice SOC
Phase 3, placebo-controlled
randomized study
Anti-CD38 mAb &
lenalidomide exposed and
BCMA-targeting therapy naïve
•
RRMM ≥3 prior lines
(dose escalation)
alnuctamab + GPRC5D CAR T
Phase 1b, dose escalation and
dose optimization study
Dose escalation: Triple class
exposed; prior BCMA or
GPRC5D therapies allowed
•
RRMM ≥3 prior lines
(dose escalation)
alnuctamab + mezigdomide
Phase 1b, dose escalation and
dose optimization study
Dose escalation: Anti-CD38
mAb exposed or naïve
Ill Bristol Myers Squibb™
Initiating Phase 3 trial in 2024
Not for Product Promotional Use
86View entire presentation